Moreover, CCL21 concentrations positively correlated with PAH development and the occurrence of PAH-related events, suggesting that this chemokine might be a promising marker for predicting the risk of SSc-related PAH and PAH progression [178]. This evidence concerns the gene CCL21 and systemic sclerosis.